Related Links Educational Materials About Clinical Trials Clinical Trials Questions to Ask Your Doctor Drug Information from MedlinePlus

Alternate Title
Basic Trial Information
Trial Description
     Purpose
     Eligibility
     Treatment/Intervention
Trial Contact Information
Registry Information

Alternate Title

Phase II Study of Theophylline in Asymptomatic Patients With Stage 0, I, or II B-cell Chronic Lymphocytic Leukemia Previously Untreated With Chemotherapy (Summary Last Modified 04/2000)

Basic Trial Information

Phase	Type	Status	Age	Sponsor	Protocol IDs
Phase II	Treatment	Completed	18 and over	NCI	E-4998 NCCTG-988151, NCT00003808, E4998

Trial Description

Purpose:

Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.

Phase II trial to study the effectiveness of theophylline in treating patients who have in situ, stage I, or stage II chronic lymphocytic leukemia.

Eligibility:

• At least 18 years old
• No previous chemotherapy
• For more information about the eligibility criteria for this trial, refer to the Health Professional version.

Final eligibility for a clinical trial is determined by the health professionals conducting the trial.

Treatment/Intervention:

Patients will receive theophylline by mouth once a day for up to 6 months. Patients will receive follow-up evaluations every 4 months for 1 year.

Important:

For more details about this trial, refer to the Health Professional version of the trial summary.

If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site.

Trial Contact Information

Trial Lead Organizations

Eastern Cooperative Oncology Group

Della Makower, MD, Protocol chair(Contact information may not be current)		Ph: 718-430-2302

North Central Cancer Treatment Group

Rajiv Pruthi, MBBS, Protocol chair		Ph: 507-284-2511 Email: pruthi.rajiv@mayo.edu

Registry Information
Official Title		Phase II Study of Theophylline in Chronic Lymphocytic Leukemia
Trial Start Date		1999-05-27
Registered in ClinicalTrials.gov		NCT00003808
Date Submitted to PDQ		1999-03-04
Information Last Verified		2007-09-21
NCI Grant/Contract Number		CA21115

Back to Top